Skip to main content
main-content

29.05.2018 | PHASE I STUDIES | Ausgabe 6/2018

Investigational New Drugs 6/2018

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors

Zeitschrift:
Investigational New Drugs > Ausgabe 6/2018
Autoren:
Sandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, Jaafar Bennouna, Mouna Sassi, Hélène de Mont-Serrat, Jean Fan, David Schnell, Jean-Pierre Delord
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s10637-018-0601-1) contains supplementary material, which is available to authorized users.
Presented in part at the European Society for Medical Oncology Congress, 28 September–2 October 2012, Vienna, Austria. Ann Oncol 2012;23(Suppl. 9);ix152–74:Abstracts 478P and 494P.

Summary

Background Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docetaxel in patients with relapsed/refractory solid tumors. Methods Patients received afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m2) or docetaxel (60 or 75 mg/m2). Dose escalation proceeded via a 3 + 3 design until the maximum tolerated dose (MTD) was reached. Adverse events (AEs), pharmacokinetics and antitumor activity were also assessed. Results Dose-limiting toxicities during Cycle 1 were reported in 6/39 patients receiving afatinib/gemcitabine (most commonly diarrhea, thrombocytopenia and vomiting) and 16/54 patients receiving afatinib/docetaxel (most commonly febrile neutropenia and stomatitis). The MTDs were established as afatinib 40 mg/gemcitabine 1000 mg/m2 and afatinib 30 mg/docetaxel 60 mg/m2. The most common drug-related AEs were diarrhea, asthenia and rash with afatinib/gemcitabine, and diarrhea, asthenia and stomatitis with afatinib/docetaxel. No relevant pharmacokinetic interactions were observed for either combination. Both combinations demonstrated clinical activity and durable disease control at the MTDs. Compared with the MTD, higher response rates were achieved with afatinib 30 mg/docetaxel 75 mg/m2 (28% vs 6%); however, this regimen was associated with problematic febrile neutropenia, an expected AE with docetaxel, that is often managed with growth factor support. Conclusions Afatinib/gemcitabine and afatinib/docetaxel demonstrated manageable safety profiles, with evidence of clinical efficacy at the MTDs. For afatinib/docetaxel, a dose level of afatinib 30 mg/docetaxel 75 mg/m2 produced higher response rates. Trial registration: NCT01251653 (ClinicalTrials.​gov).

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
ESM 1 (DOCX 20 kb)
10637_2018_601_MOESM1_ESM.docx
Supplementary Table 1 (DOCX 16 kb)
10637_2018_601_MOESM2_ESM.docx
Supplementary Table 2 (DOCX 16 kb)
10637_2018_601_MOESM3_ESM.docx
Supplementary Table 3 (DOCX 17 kb)
10637_2018_601_MOESM4_ESM.docx
Supplementary Table 4 (DOCX 17 kb)
10637_2018_601_MOESM5_ESM.docx
High Resolution (EPS 1602 kb)
10637_2018_601_MOESM6_ESM.eps
High Resolution (EPS 1620 kb)
10637_2018_601_MOESM7_ESM.eps
High Resolution (EPS 1618 kb)
10637_2018_601_MOESM8_ESM.eps
High Resolution (EPS 1981 kb)
10637_2018_601_MOESM9_ESM.eps
High Resolution (EPS 1621 kb)
10637_2018_601_MOESM10_ESM.eps
High Resolution (EPS 1624 kb)
10637_2018_601_MOESM11_ESM.eps
High Resolution (EPS 1616 kb)
10637_2018_601_MOESM12_ESM.eps
High Resolution (EPS 1619 kb)
10637_2018_601_MOESM13_ESM.eps
High Resolution (EPS 1961 kb)
10637_2018_601_MOESM14_ESM.eps
High Resolution (EPS 1951 kb)
10637_2018_601_MOESM15_ESM.eps
High Resolution (EPS 1973 kb)
10637_2018_601_MOESM16_ESM.eps
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2018

Investigational New Drugs 6/2018 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise